{"id":"NCT03834506","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)","officialTitle":"A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-02","primaryCompletion":"2022-06-20","completion":"2023-07-18","firstPosted":"2019-02-08","resultsPosted":"2023-06-18","lastUpdate":"2025-07-18"},"enrollment":1030,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Prostatic Neoplasms"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"Docetaxel","otherNames":["TAXOTERE®"]},{"type":"DRUG","name":"Prednisone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":["Normal saline or dextrose infusion"]},{"type":"DRUG","name":"Dexamethasone","otherNames":["DECADRON®"]}],"arms":[{"label":"Pembrolizumab+Docetaxel","type":"EXPERIMENTAL"},{"label":"Placebo+Docetaxel","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC but have progressed on or are intolerant to Next Generation Hormonal Agent (NHA).\n\nThere are two primary study hypotheses.\n\nHypothesis 1: The combination of pembrolizumab plus docetaxel plus prednisone is superior to placebo plus docetaxel plus prednisone with respect to Overall Survival (OS).\n\nHypothesis 2: The combination of pembrolizumab plus docetaxel plus prednisone is superior to placebo plus docetaxel plus prednisone with respect to Radiographic Progression-free Survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Up to 36.5 months","effectByArm":[{"arm":"Pembrolizumab + Docetaxel","deltaMin":19.6,"sd":null},{"arm":"Placebo + Docetaxel","deltaMin":19,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1677"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":10},"locations":{"siteCount":215,"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","Chile","China","Colombia","France","Germany","Ireland","Israel","Italy","Japan","Netherlands","Russia","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["40043230","34098744"],"seeAlso":["http://merckclinicaltrials.com/","https://msd.trialsummaries.com/Study/StudyDetails?id=26073&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":212,"n":514},"commonTop":["Diarrhoea","Alopecia","Fatigue","Anaemia","Asthenia"]}}